PureTech Health plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PTCHF research report →
Price Chart
About the company
PureTech Health plc operates as a clinical-stage biopharmaceutical enterprise, concentrating its efforts in the United States on the discovery, advancement, and market introduction of novel therapeutic solutions. The company's diverse pipeline targets a wide array of challenging medical conditions, including inflammatory, fibrotic, and immunological disorders, intractable cancers, various lymphatic and gastrointestinal issues, as well as neurological and neuropsychological ailments. Among its significant offerings, PureTech provides KarXT, a treatment designed to modulate muscarinic acetylcholine receptors for managing schizophrenia and the psychosis seen in Alzheimer's disease.
- CEO
- Robert Lyne
- IPO
- 2015
- Employees
- 80
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on PTCHF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $380.95M
- P/E
- -3.46
- PEG
- 0.01
- P/S
- 82.99
- P/B
- 1.23
- EV/EBITDA
- -1.61
- Div Yield
- 0.00%
- Gross Margin
- -468.52%
- Op Margin
- -2113.80%
- Net Margin
- -2355.32%
- ROE
- -31.98%
- ROIC
- -19.72%
Latest fiscal year · YoY change
- Revenue
- $4.76M+10.4%
- Gross Profit
- $1.34M-68.9%
- Op Income
- $-100,717,207
- Net Income
- $-112,179,583-309.6%
- EPS
- $-0.47-335.0%
- OCF Growth
- +35.2%
- FCF Growth
- +35.2%
- 52W High
- $1.92
- 52W Low
- $1.53
- 50D MA
- $1.62
- 200D MA
- $1.68
- Beta
- 0.79
- RSI (14)
- 41
- Avg Volume
- 2.39K
No earnings-call transcripts are available for PTCHF yet.
- Free Float
- 89.3%
- Shares Outstanding
- 243.42M
- Float Shares
- 217.34M
Our PTCHF coverage
Recent articles, reports, and earnings notes.
No research on PTCHF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PTCHF report →PureTech Health: Results of Annual General Meeting
businesswire.com · Jun 10
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
proactiveinvestors.com · May 1
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
proactiveinvestors.co.uk · May 1
PureTech Health plc (PRTC) Q4 2025 Earnings Call Transcript
seekingalpha.com · Apr 29
Short Interest in PureTech Health plc (OTCMKTS:PTCHF) Expands By 69.4%
defenseworld.net · Feb 14
Cavendish sees Poolbeg’s POLB 001 gaining strategic importance as CRS research expands
proactiveinvestors.com · Dec 8
Greengage plans AQSE float with bold Bitcoin-backed lending strategy
proactiveinvestors.com · Dec 8
Puretech gains after FDA meeting post-Phase II trial
proactiveinvestors.com · Dec 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.